Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI

• Verfasst von: Hope, Thomas A. [VerfasserIn]
• Verfasst von: Afshar-Oromieh, Ali [VerfasserIn]
• Verfasst von: Eiber, Matthias [VerfasserIn]
• Titel: Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI
• Titelzusatz: current and future applications
• Verf.angabe: Thomas A. Hope, Ali Afshar-Oromieh, Matthias Eiber, Louise Emmett, Wolfgang P. Fendler, Courtney Lawhn-Heath, Steven P. Rowe
• E-Jahr: 2018
• Jahr: August 2018
• Umfang: 9 S.
• Teil: volume:211
• Teil: year:2018
• Teil: number:2
• Teil: pages:286-294
• Teil: extent:9
• Fussnoten: Gesehen am 11.06.2019
• Titel Quelle: Enthalten in: American journal of roentgenology
• Ort Quelle: Leesburg, Va. : American Roentgen Ray Society, 1965
• Jahr Quelle: 2018
• Band/Heft Quelle: 211(2018), 2, Seite 286-294
• ISSN Quelle: 1546-3141
• DOI: doi:10.2214/AJR.18.19957
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: PET
• Sach-SW: PET/MRI
• Sach-SW: prostate cancer
• Sach-SW: prostate-specific membrane antigen
• K10plus-PPN: 1667199706

Abstract

Prostate-Specific Membran...Notes on InterpretationClinical ApplicationsPET/CT Versus PET/MRIFuture ApplicationsPath Toward ApprovalConclusionReferences OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.